Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1251-1260 Newer>

Bio-IT World June 17, 2004 Mark D. Uehling	How to Spell Discovery Rapidly combining cosmos of chemical and biological data, Johnson & Johnson's multidisciplinary ABCD platform for drug discovery aims to give scientists access to more information -- and the ability to make better decisions
Bio-IT World June 17, 2004 Hope Melville	Is It Safe? Think the safe harbor provision in patent law lets you use patented compounds in all preclinical-phase research? Think again.
Bio-IT World June 17, 2004 Stephanie McRae	Expatriate Your Patents Intellectual property rights, especially patents, are often the principal source of value and revenue for biotechnology companies. You can save a boatload of tax money shipping your IP rights overseas.
Bio-IT World June 17, 2004 Cathryn Campbell	Patent Plaintiff Perils Suing for patent infringement may seem rewarding, but you could lose even more.
Bio-IT World June 17, 2004 John Garvey	Rational Decisions As companies in the computationally guided rational drug design sector mature, they should be more sure of the boundaries that surround their proprietary technologies.
Bio-IT World June 17, 2004 John Russell	Systems Biology - Now Leaving on Track 1 Entelos, a leader in predictive biosimulation, partners with pharmaceutical and biotech organizations worldwide to develop effective new treatments for disease. Michael French, chief business officer at Entelos, explains what powers the systems biology engine.
Bio-IT World June 17, 2004 Michael A. Goldman	A Hip Approach to Gene Hunting IntegraGen defines the genetic blueprint of complex human diseases and delivers validated disease markers and therapeutic targets for a better diagnosis and a causal treatment of common diseases, based on its unique genomic analysis expertise.
Bio-IT World June 17, 2004	Minority Report With Iressa, the AstraZeneca drug approved by the FDA last year, there is a small group, maybe 10 to 20 percent of lung cancer patients, who get an almost miraculous response. Mutations may explain patient responses to the drug.
Bio-IT World June 17, 2004 Michael A. Greeley	A Bet on Biomarkers Biomarkers are a hot topic among venture capitalists these days and while they are becoming increasingly important in drug discovery and delivery processes, there is great debate about the best business models for marketing the related tools.
Bio-IT World June 17, 2004 Robert M. Frederickson	Microarray Analysis Reaches the Desktop Various commercial solutions exist to analyze microarray data, from enterprise-level solutions designed primarily for large companies and institute-based support facilities to the more recently emerged desktop solutions for individual research labs.
<Older 1251-1260 Newer> Return to current articles.